Skip to main content
Erschienen in: Applied Health Economics and Health Policy 6/2014

01.12.2014 | Original Research Article

Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland

verfasst von: Emer Fogarty, Cathal Walsh, Christopher McGuigan, Niall Tubridy, Michael Barry

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Multiple sclerosis (MS) has significant financial consequences for healthcare systems, individual patients and households, and the wider society. This study examines the distribution of MS costs and resource utilisation across cost categories and from various perspectives, as MS disability increases.

Methods

Two hundred and fourteen patients with MS were recruited from a specialist MS outpatient clinic in Ireland and included in an interview-based study on MS-related healthcare resource consumption and costs. Patients were grouped into three categories based on disability: mild [Expanded Disability Status Scale (EDSS) score 0–3.5, n = 114], moderate (EDSS 4.0–6.5, n = 72) and severe (EDSS 7.0–9.5, n = 27). The mean annual direct and indirect costs (in year 2012 values) were estimated using non-parametric bootstrapping.

Results

Participants were 66.4 % female, with a mean age of 47.6 years and a mean EDSS score of 3.6. The majority had relapsing-remitting MS (RRMS) (53 %). The mean annual direct (indirect) costs per person were €10,249 (€9,447), €13,045 (€31,806) and €56,528 (€39,440) in mild, moderate and severe MS, respectively. Direct costs are driven by the cost of disease-modifying therapies and professional home help in mild and severe MS, respectively. Between 74 % (severe MS) and 96 % (mild MS) of all direct costs are borne by the healthcare payer, the remainder being incurred by patients, their families or other non-healthcare organisations.

Conclusions

MS is associated with high levels of healthcare resource consumption and costs, and these costs increase with increasing disability. There is potential to significantly reduce the economic burden of MS through interventions that prevent progression from mild or moderate MS to severe MS, help support independent living at home and keep people with MS in the work force.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–15.PubMedCrossRef Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–15.PubMedCrossRef
2.
Zurück zum Zitat Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907–11.PubMedCrossRef Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907–11.PubMedCrossRef
4.
Zurück zum Zitat Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, et al. Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry. 2011;82(3):317–22. doi:10.1136/jnnp.2010.220988.PubMedCrossRef Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, et al. Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry. 2011;82(3):317–22. doi:10.​1136/​jnnp.​2010.​220988.PubMedCrossRef
5.
Zurück zum Zitat Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N. Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Mult Scler. 2013. doi:10.1177/1352458512474860. Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N. Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Mult Scler. 2013. doi:10.​1177/​1352458512474860​.
6.
Zurück zum Zitat Beer S, Khan F, Kesselring J. Rehabilitation interventions in multiple sclerosis: an overview. J Neurol. 2012;259(9):1994–2008.PubMedCrossRef Beer S, Khan F, Kesselring J. Rehabilitation interventions in multiple sclerosis: an overview. J Neurol. 2012;259(9):1994–2008.PubMedCrossRef
7.
Zurück zum Zitat Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(1):133–46.PubMedCrossRef Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(1):133–46.PubMedCrossRef
8.
Zurück zum Zitat Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.PubMedCrossRef Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.PubMedCrossRef
9.
Zurück zum Zitat Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696–702.PubMedCrossRef Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696–702.PubMedCrossRef
10.
Zurück zum Zitat McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics. 2008;26(10):847–60.PubMedCrossRef McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics. 2008;26(10):847–60.PubMedCrossRef
11.
Zurück zum Zitat Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918–26.PubMedCentralPubMedCrossRef Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918–26.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Casado V, Martinez-Yelamos S, Martinez-Yelamos A, Carmona O, Alonso L, Romero L et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Services Research. 2006;6. Casado V, Martinez-Yelamos S, Martinez-Yelamos A, Carmona O, Alonso L, Romero L et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Services Research. 2006;6.
13.
Zurück zum Zitat Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler. 2012;18(5):662–8.PubMedCrossRef Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler. 2012;18(5):662–8.PubMedCrossRef
14.
Zurück zum Zitat Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.PubMedCrossRef Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.PubMedCrossRef
15.
Zurück zum Zitat Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med. 2000;343(13):898–904.CrossRef Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med. 2000;343(13):898–904.CrossRef
16.
Zurück zum Zitat Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2009;374(9700):1503–11.CrossRef Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2009;374(9700):1503–11.CrossRef
17.
Zurück zum Zitat Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRef Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRef
18.
Zurück zum Zitat Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. 2nd ed. London: Gaskell; 2001. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. 2nd ed. London: Gaskell; 2001.
19.
Zurück zum Zitat Clarke PM, Fiebig DG, Gerdtham UG. Optimal recall length in survey design. J Health Econ. 2008;27(5):1275–84.PubMedCrossRef Clarke PM, Fiebig DG, Gerdtham UG. Optimal recall length in survey design. J Health Econ. 2008;27(5):1275–84.PubMedCrossRef
21.
Zurück zum Zitat Central Statistics Office. Earnings and labour costs. Ireland: Central Statistics Office; 2013. Central Statistics Office. Earnings and labour costs. Ireland: Central Statistics Office; 2013.
22.
Zurück zum Zitat Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444–52.PubMedCrossRef Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444–52.PubMedCrossRef
24.
Zurück zum Zitat Health Service Executive Primary Care Reimbursement Service (HSE-PCRS). Statistical analysis of claims and payments 2011. Dublin 2012. Health Service Executive Primary Care Reimbursement Service (HSE-PCRS). Statistical analysis of claims and payments 2011. Dublin 2012.
25.
Zurück zum Zitat Association of British Neurologists. Revised (2009) Association of British neurologists’ guidelines for prescribing in multiple sclerosis. London; 2009. Association of British Neurologists. Revised (2009) Association of British neurologists’ guidelines for prescribing in multiple sclerosis. London; 2009.
26.
Zurück zum Zitat Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRef Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRef
27.
Zurück zum Zitat Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.PubMedCrossRef Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.PubMedCrossRef
28.
Zurück zum Zitat Rotstein DL, Mamdani M, O’Connor PW. Increasing use of disease modifying drugs for MS in Canada. Can J Neurol Sci. 2010;37(3):383–8.PubMed Rotstein DL, Mamdani M, O’Connor PW. Increasing use of disease modifying drugs for MS in Canada. Can J Neurol Sci. 2010;37(3):383–8.PubMed
29.
Zurück zum Zitat Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011;6(11):e22444.PubMedCentralPubMedCrossRef Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011;6(11):e22444.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, Van Der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA J Am Med Assoc. 2012;308(3):247–56.CrossRef Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, Van Der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA J Am Med Assoc. 2012;308(3):247–56.CrossRef
31.
Zurück zum Zitat Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013. doi:10.3111/13696998.2013.807267. Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013. doi:10.​3111/​13696998.​2013.​807267.
33.
Zurück zum Zitat Health Service Executive (HSE) Casemix Unit: ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2010 costs and activity. 2012. Health Service Executive (HSE) Casemix Unit: ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2010 costs and activity. 2012.
Metadaten
Titel
Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland
verfasst von
Emer Fogarty
Cathal Walsh
Christopher McGuigan
Niall Tubridy
Michael Barry
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 6/2014
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-014-0128-3

Weitere Artikel der Ausgabe 6/2014

Applied Health Economics and Health Policy 6/2014 Zur Ausgabe